1,693 Shares in Biogen Inc. (NASDAQ:BIIB) Bought by Headlands Technologies LLC

Headlands Technologies LLC purchased a new position in Biogen Inc. (NASDAQ:BIIB) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,693 shares of the biotechnology company’s stock, valued at approximately $438,000.

Other large investors also recently bought and sold shares of the company. OFI Invest Asset Management bought a new stake in Biogen in the third quarter worth $26,000. Gladius Capital Management LP bought a new position in Biogen during the third quarter valued at $28,000. KB Financial Partners LLC increased its position in Biogen by 105.1% during the third quarter. KB Financial Partners LLC now owns 121 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 62 shares during the last quarter. CVA Family Office LLC bought a new position in Biogen during the fourth quarter valued at $36,000. Finally, Baker Avenue Asset Management LP increased its position in Biogen by 215.5% during the third quarter. Baker Avenue Asset Management LP now owns 183 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 125 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on BIIB shares. William Blair reiterated an “outperform” rating on shares of Biogen in a research report on Monday, April 1st. Wedbush boosted their price objective on shares of Biogen from $213.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday. Bank Of America (Bofa) cut their price objective on shares of Biogen from $290.00 to $280.00 and set a “neutral” rating on the stock in a research report on Monday, February 12th. Robert W. Baird lowered their target price on shares of Biogen from $333.00 to $316.00 and set an “outperform” rating for the company in a research note on Wednesday, February 14th. Finally, StockNews.com lowered shares of Biogen from a “buy” rating to a “hold” rating in a research note on Tuesday, February 20th. Ten equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, Biogen has a consensus rating of “Moderate Buy” and an average price target of $293.88.

Insider Buying and Selling

In related news, insider Priya Singhal sold 419 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $239.45, for a total value of $100,329.55. Following the transaction, the insider now owns 4,516 shares in the company, valued at approximately $1,081,356.20. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, insider Priya Singhal sold 419 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $239.45, for a total value of $100,329.55. Following the transaction, the insider now owns 4,516 shares in the company, valued at approximately $1,081,356.20. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Eric K. Rowinsky purchased 455 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was acquired at an average price of $222.54 per share, for a total transaction of $101,255.70. Following the acquisition, the director now owns 20,629 shares in the company, valued at approximately $4,590,777.66. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 882 shares of company stock worth $202,030. 0.60% of the stock is owned by company insiders.

Biogen Stock Up 3.2 %

Shares of BIIB traded up $6.44 during mid-day trading on Friday, hitting $208.90. 1,894,098 shares of the company traded hands, compared to its average volume of 1,185,437. Biogen Inc. has a 1-year low of $189.44 and a 1-year high of $319.76. The company has a quick ratio of 1.26, a current ratio of 2.10 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $30.42 billion, a PE ratio of 26.08, a price-to-earnings-growth ratio of 2.06 and a beta of -0.02. The business has a 50 day moving average of $212.55 and a 200 day moving average of $233.78.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, April 24th. The biotechnology company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.45 by $0.22. Biogen had a net margin of 12.07% and a return on equity of 14.83%. The firm had revenue of $2.29 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same quarter in the prior year, the company posted $3.40 earnings per share. The company’s revenue for the quarter was down 7.0% compared to the same quarter last year. Equities research analysts anticipate that Biogen Inc. will post 15.55 EPS for the current year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.